CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
News
CureVac’s COVID-19 vaccine begins rolling review with EMA
CureVac’s CVnCoV is currently being investigated in a randomised, placebo-controlled Phase IIb/III clinical trial
UK expands COVID-19 vaccinations to over-65s after 15 million receive first dose
People aged 65 to 69 and the clinically vulnerable will be offered the jab from today
Entry deadline extended for INTCR 2021
The entry deadline for the 2021 International Clinical Researcher of the Year has been extended to the 16th of April.
Chiesi launches pilot inhaler recycling scheme in the UK
Scheme will run for 12 months in the Leicester, Leicestershire and Rutland areas
Roche’s vision loss therapy faricimab extends time between treatments by up to four months
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE
NICE determined that there were uncertainties around the cost-effectiveness of the therapy
NHS to roll-out tocilizumab treatment for COVID-19
In the RECOVERY trial, tocilizumab treatment significantly reduced deaths caused by COVID-19
Rentschler Biopharma to build cell and gene therapy manufacturing capabilities in the UK
German CDMO will build new manufacturing capabilities at CGT Catapult site
UK government proposes reforms for health and social care following pandemic
Future reforms will aim to bring health and care services closer together
Novo Nordisk’s semaglutide cuts body weight in large-scale trial
Participants lost on average 14.9% of their baseline body weight
WHO panel recommends AZ/Oxford’s COVID-19 vaccine
WHO’s SAGE panel backs wide use of jab in adults, including in people aged over 65
Synairgen’s inhaled COVID-19 treatment included in US trial
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
NIHR funds study aiming to improve the lives of people with cystic fibrosis
The CF STORM trial will seek to address how the treatment burden for people with CF can be reduced
US approval for Libtayo in advanced basal cell carcinoma
First immunotherapy indicated for certain BCC patients
